This is a protocol preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Method Article
Rampyari Walia
Targefect Transfection Group, Targeting Systems
Corresponding Author
License:
This work is licensed under a CC BY-NC 3.0 License. Read Full License
Efficient gene transfer into primary endothelial cells is an important prerequisite for studying regulation of gene expression in vascular tissue. Here we present a simple set of protocols using the Targefect-HUVEC TM transfection kit to transfect HUVECs, HMVECs, BAECs and different types of primary endothelial cells. The kit consists of Targefect F-2 , a non-lipid cationic transfection reagent with low toxicity along with two enhancer formulations- Virofect TM and a Peptide Enhancer. Virofect enhances gene transfer by using adenoviral receptors on the cell surface to enhance intracellular delivery of transfection complexes. Once the transfection complex is internalized, Virofect helps the transfection complex escape degradation in the lysosome and enhances the both duration and efficiency of transgene expression. The Peptide Enhancer increases efficiency of transgene expression by escorting genes to the nucleus. Using the protocols mentioned here researchers have been able to achieve 70-80% transfection efficiencies in HUVECs and efficiencies ranging form 70-80% in human and bovine lung microvascular cells (see attached figures showing data from other lab groups and a list of product citations "http://www.targetingsystems.net/pdf/Targefect_HUVEC.pdf":http://www.targetingsystems.net/pdf/Targefect_HUVEC.pdf )
Keywords
Targefect Transfection Protocols, HUVEC, Human Umbilical Vein Endothelial Cells, HMVECs , Human Microvascular Endothelial Cells
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
None
Loading...
Version History
CURRENT STATUS: Posted
Version 1
Posted 12 May, 2011
No community comments so far
Metrics
Comments: 0
HTML Views: ...
Subject Areas
Biotechnology
Method Article
Rampyari Walia
Targefect Transfection Group, Targeting Systems
Corresponding Author
Version History
CURRENT STATUS: Posted
Version 1
Posted 12 May, 2011
No community comments so far
Metrics
Comments: 0
HTML Views: ...
Subject Areas
Biotechnology
License:
This work is licensed under a CC BY-NC 3.0 License. Read Full License
Efficient gene transfer into primary endothelial cells is an important prerequisite for studying regulation of gene expression in vascular tissue. Here we present a simple set of protocols using the Targefect-HUVEC TM transfection kit to transfect HUVECs, HMVECs, BAECs and different types of primary endothelial cells. The kit consists of Targefect F-2 , a non-lipid cationic transfection reagent with low toxicity along with two enhancer formulations- Virofect TM and a Peptide Enhancer. Virofect enhances gene transfer by using adenoviral receptors on the cell surface to enhance intracellular delivery of transfection complexes. Once the transfection complex is internalized, Virofect helps the transfection complex escape degradation in the lysosome and enhances the both duration and efficiency of transgene expression. The Peptide Enhancer increases efficiency of transgene expression by escorting genes to the nucleus. Using the protocols mentioned here researchers have been able to achieve 70-80% transfection efficiencies in HUVECs and efficiencies ranging form 70-80% in human and bovine lung microvascular cells (see attached figures showing data from other lab groups and a list of product citations "http://www.targetingsystems.net/pdf/Targefect_HUVEC.pdf":http://www.targetingsystems.net/pdf/Targefect_HUVEC.pdf )
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Loading...